Fermion specializes in AI-enabled drug discovery and modalities for identifying small molecule drugs to progress towards Phases 1 and 2 clinical trials

Here at Fermion, we integrate several cutting-edge technologies across AI, Biology, medicinal chemistry and medicine to develop innovative drug therapies. Our use of advanced techniques such as deep learning, reinforcement learning, generative adversarial networks, big data, and knowledge graphs helps us enhance drug development. This strategy will ultimately lead to refined preclinical research and offer superior treatment options for a variety of diseases.

Read More

AI technology is breaking new ground in drug development,

expanding possibilities

and boundaries

AI Drug Discovery Solution

By incorporating AI technology into the traditional drug discovery pathway and leveraging Fermion’s Drug Studio AI platform, we can efficiently generate molecules with optimal comprehensive parameters. By utilizing this approach, Fermion can specialize in rapid design, large-scale screening, and precise calculations to effectively improves the success rate of drug discovery.

Read More


Currently our pipeline has a refined focus on developing differentiated BIC/FIC products that target novel targets in neurology and autoimmune diseases. With an emphasis on improved target selectivity and tissue targeting, we have demonstrated success by establishing more than ten small molecule drug programs. We structure partnerships to facilitate the development of high-potential assets from promising research into proven medicines.

Read More

asset in Phase 1


assets in IND-enabling studies


wholly-owned programs


named Platform-generated drug programs





Guanzhou Life Science Innovation Center, Room 2502, Tower A, Haizhu District, Guangzhou, GUANGDONG, China

Read More